Yeom Seung-Seop, Park In Ja, Jung Sung Woo, Oh Se Heon, Lee Jong Lyul, Yoon Yong Sik, Kim Chan Wook, Lim Seok-Byung, Kim Nayoung, Yu Chang Sik, Kim Jin Cheon
Department of Colon and Rectal Surgery Department of Clinical Epidemiology and Biostatistics, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
Medicine (Baltimore). 2017 Oct;96(43):e8249. doi: 10.1097/MD.0000000000008249.
We compared the oncological outcomes of sphincter-saving resection (SSR) and abdominoperineal resection (APR) in 409 consecutive patients with very low rectal cancer (i.e., tumors within 3 cm from the anal verge); 335 (81.9%) patients underwent APR and 74 (18.1%) underwent SSR. The APR group comprised higher proportions of men (67.5% vs 55.4%, P = .049) and advanced-stage patients (P < .001). Preoperative chemoradiotherapy (PCRT) was more frequently administered in the SSR group (83.8% vs 52.8%, P < .001). Overall, the systemic and local recurrence rates were 29.1% and 6.1%, respectively. On stratification according to PCRT and pathologic stage, the mode of surgery did not affect the recurrence type. Moreover, recurrence-free survival (RFS) did not differ according to the mode of surgery in different cancer stages. RFS was associated with ypT and ypN stages in patients who received PCRT, while pN stage, lymphovascular invasion (LVI), and circumferential resection margin (CRM) involvement were risk factors for RFS in those who did not receive PCRT. Notably, SSR was not found to be a risk factor for RFS in either subgroup. Patients who were stratified according to cancer stage and PCRT also showed no differences in RFS according to the mode of surgery. Our results demonstrate that, regardless of PCRT administration, SSR is an effective treatment for very low rectal cancer, while CRM is an important prognostic factor for patients who did not receive PCRT.
我们比较了409例连续的极低位直肠癌(即肿瘤距肛缘3厘米以内)患者行保肛手术(SSR)和腹会阴联合切除术(APR)的肿瘤学结局;335例(81.9%)患者接受了APR,74例(18.1%)接受了SSR。APR组男性比例(67.5%对55.4%,P = 0.049)和晚期患者比例更高(P < 0.001)。SSR组更频繁地进行术前放化疗(PCRT)(83.8%对52.8%,P < 0.001)。总体而言,全身和局部复发率分别为29.1%和6.1%。根据PCRT和病理分期分层后,手术方式不影响复发类型。此外,不同癌症分期的患者,无复发生存期(RFS)根据手术方式并无差异。接受PCRT的患者中,RFS与ypT和ypN分期相关,而未接受PCRT的患者中,pN分期、淋巴管侵犯(LVI)和环周切缘(CRM)受累是RFS的危险因素。值得注意的是,在任何一个亚组中均未发现SSR是RFS的危险因素。根据癌症分期和PCRT分层的患者,其RFS根据手术方式也无差异。我们的结果表明,无论是否进行PCRT,SSR都是极低位直肠癌的有效治疗方法,而CRM是未接受PCRT患者的重要预后因素。